NATCO Pharma launches generic blood cancer treatment medicine in U.S.

NATCO Pharma on Tuesday announced the launch of generic Pomalidomide capsules indicated for treatment of adult patients with blood and bone marrow cancer in the U.S. market in partnership with Breckenridge Pharmaceutical, Inc.

Pomalidomide capsule is a generic version of Pomalyst by Celgene.

The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics, NATCO Pharma said in a regulatory filing.

Commenting on the launch, Vice Chairman and CEO Rajeev Nannapaneni said,”…this further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide.”

He further said,”We look forward to bringing more such complex and specialty products to the market in the coming years.” Breckenridge Pharmaceutical, Inc President and Chief Commercial Officer, Brian Guy said,”Breckenridge’s launch of Pomalidomide capsules delivers a high-quality, affordable generic solution, supported by copay assistance for eligible patients to help reduce treatment delays and ensure continuity of care.”

Access and affordability continue to be major challenges for patients who depend on specialty therapies, Guy noted.

NATCO Pharma said Pomalidomide capsules are indicated for treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma, the company added.

Pomalidomide Capsules, 1mg, 2mg, 3mg and 4mg, had estimated sales of USD 3.2 billion in the U.S. for 12 months ended September 2025 as per industry sales data, it said.

NATCO believes based on information made available by the U.S. Food and Drug Administration (FDA), it has 180 days of shared exclusivity for marketing the drug.